In mice with non-alcoholic fatty liver disease (NAFLD), the administration of chlorogenic acid resulted in an increase in intestinal flora and the secretion of glucagon-like peptide-1 (GLP-1), which is known to regulate inflammation (Shi et al., 2021) (Figure 6; Table 9). Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.